Vascular enhancement in early dynamic liver MR imaging in an animal model: Comparison of two injection regimen and two different doses Gd-EOB-DTPA (Gadoxetic Acid) with standard Gd-DTPA

Investigative Radiology

Volumn 44, Issue 6, 2009, Pages 305-310

  Zech, Christoph J ^a   Vos, Bernhard ^b   Nordell, Anders ^c   Urich, Matthias ^b   Blomqvist, Lennart ^c   Breuer, Josy ^b   Reiser, Maximilian F ^a   Weinmann, Hanns Joachim ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Dynamic liver MR; Extracellular enhancement; Gd EOB DTPA (Gadoxetic Acid); Injection protocols

Indexed keywords

GADOXETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL STUDY; HEPATOGRAPHY; INFERIOR CAVA VEIN; LIVER PARENCHYMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN; PRIORITY JOURNAL; RADIATION DOSE; RANK SUM TEST; SIGNAL NOISE RATIO; STATISTICAL SIGNIFICANCE; SWINE;

EID: 67651119949     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181a24512     Document Type: Article

References (26)

1. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol. 2005;39:401-412.
2. Bartolozzi C, Cioni D, Donati F, et al. Focal liver lesions: MR imagingpathologic correlation. Eur Radiol. 2001;11:1374-1388.
3. Tomemori T, Yamakado K, Nakatsuka A, et al. Fast 3D dynamic MR imaging of the liver with MR SmartPrep: comparison with helical CT in detecting hypervascular hepatocellular carcinoma. Clin Imaging. 2001;25: 355-361.
4. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034-1042.
5. Mortele KJ, Praet M, Van Vlierberghe H, et al. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI. Abdom Imaging. 2002;27:700-707.
6. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59-67.
7. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acidenhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
8. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U. S. multicenter phase III study. Radiology. 2005;237:89-98.
9. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology. 1999;212:876-884.
10. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOBDTPA. Magn Reson Med Sci. 2007;6:43-52.
11. Yoshikawa K, Inoue Y, Shimada M, et al. Contrast-enhanced MR angiography in rats with hepatobiliary contrast agents. Magn Reson Imaging. 2004; 22:937-942.
12. Zangos S, Hammerstingl R, Mack MG, et al. Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA. Rofo. 2001; 173:1034-1040.
13. Nelson RC, Umpierrez ME, Chezmar JL, et al. Delayed magnetic resonance hepatic imaging with gadolinium-DTPA. Invest Radiol. 1988;23:509-511.
14. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172.
15. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOBDTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
16. Schuhmann-Giampieri G, Mahler M, Röll G, et al. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol. 1997;37:587-596.
17. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol.. 2005;40:715-724.
18. Nikolaou K, Schoenberg SO, Brix G, et al. Quantification of pulmonary blood flow and volume in healthy volunteers by dynamic contrast-enhanced magnetic resonance imaging using a parallel imaging technique. Invest Radiol. 2004;39:537-545.
19. Awai K, Takada K, Onishi H, et al. Aortic and hepatic enhancement and tumor-to-liver contrast: analysis of the effect of different concentrations of contrast material at multi-detector row helical CT. Radiology. 2002;224:757-763.
20. Awai K, Inoue M, Yagyu Y, et al. Moderate versus high concentration of contrast material for aortic and hepatic enhancement and tumor-to-liver contrast at multi-detector row CT. Radiology. 2004;233:682-688.
21. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3. 0T-MR imaging with pathologic correlation. Invest Radiol. 2008;43:538-546.
22. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
23. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468-478.
24. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
25. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocytespecific contrast medium. Invest Radiol. 2008;43:809-815.
26. Willatt JM, Hussain HK, Adusumilli S, et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330.